Efficacy of ramatroban in multiple sclerosis patients
Not Applicable
Completed
- Conditions
- Multiple sclerosis
- Registration Number
- JPRN-UMIN000002725
- Lead Sponsor
- Iou hospital
- Brief Summary
All of the patients were treated with ramatroban (150 mg/day p.o.) added to conventinal MS therapy. The numbers of relapses were used as primary outcome measures. The patients were monitored for the adverse effects. A patient with acute eruption by drug allergy discontinued ramatroban. Four of 5 patients could continue ramatroban treatment without any adverse effects. In 4 patients who could complete two years of therapy, there was significant difference in the mean annual relapse rates (before 4.0+/-2.8 SD; on ramatroban 0.8+/-0.5 SD ).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
pregnant woman
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Suppression of the new lesion in the brain MRI
- Secondary Outcome Measures
Name Time Method